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Still a Concern?*Marina Urena, MD, Josep Rodés-Cabau, MDT ranscatheter aortic valve replacement (TAVR)has become the ﬁrst-choice therapy for pa-tients with symptomatic aortic stenosis and
contraindications for cardiac surgery and a thera-
peutic alternative for those at high-risk of periopera-
tive mortality. TAVR has experienced a very rapid
worldwide expansion in recent years, and ongoing
studies are currently evaluating its application in
intermediate-risk populations. However, several limi-
tations of this technology have been identiﬁed, some
of which could potentially jeopardize its expansion
to the treatment of a lower-risk population.SEE PAGE 60The occurrence of new conduction disturbances
after TAVR, particularly left bundle branch block and
the need for permanent pacemaker (PPM), is still a
matter of concern because of the very high frequency
of these complications and their potential negative
impact on late outcomes (1). The results from the
PARTNER (Placement of Aortic Transcatheter Valve)
trial (randomized and nonrandomized continuous
access cohorts) regarding the occurrence, predictors,
and impact of PPM implantation following TAVR are
reported by Nazif et al. (2) in this issue of JACC:
Cardiovascular Interventions. In a cohort of 1,973 pa-
tients undergoing TAVR with a balloon-expandable
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due to the occurrence of complete atrioventricular
block (AVB) in most cases. Of note, a much higher
incidence of PPM was observed in the more recent
nonrandomized continuous access cohort (9.6%) than
in the earlier randomized cohort (5.6%), and such
differences persisted after further adjustment for po-
tential confounders in a multivariate analysis. Al-
though the reasons for such a signiﬁcant increase
in PPM implantation over time are poorly understood,
this ﬁnding indicates that this complication of TAVR is
not going to be solved only by increasing the centers’/
operators’ experience. In addition, although enhanced
antiparavalvular leak properties and improved
retrievability/repositionability capabilities are ex-
pected with newer balloon- and self-expandable TAVR
technologies, no speciﬁc features seem to have been
implemented to reduce this complication.
The spatial proximity between the aortic valve and
the conduction system (atrioventricular node and left
bundle branch block), which lies in the ventricular
septum a few millimeters below the aortic root com-
plex (3), explains the risk of AVB when the stent
frame of the transcatheter valve prosthesis mechani-
cally interacts with the ventricular septum. In fact,
an indirect measurement of the pressure exerted by
the stent frame on the ventricular septum (prosthesis
diameter/left ventricular outﬂow tract diameter ratio)
was an independent predictor of the occurrence of
AVB in the work by Nazif et al. (2), along with other
well-known predictors such as the presence of right
bundle branch block (1,2,4). Unfortunately, the depth
of the valve prosthesis, 1 of the most important
factors associated with PPM in prior studies (1),
was not available in the study by Nazif et al. (2),
and whether or not valve oversizing predicted
TABLE 1 Main Studies Assessing the Effect of PPM Implantation After Cardiac Surgery and Transcatheter Aortic Valve Replacement
First Author, Year
(Ref. #) N Intervention
Age,
yrs
LVEF,
%
Incidence
PPM, %
Mean/Median
Follow-Up, yrs Endpoints
Results
(PPM vs. no PPM)
Long-Term
Pacing
Bagur et al., 2011 (16) 780 SAVR 77  4 60  13 3.2 3.3 Mortality 4% vs. 26%,
p ¼ 0.12
NA
Raza et al., 2011 (17) 6,268 Any cardiac
surgery
66  10 50  10 2.2 7.2  5.0 Mortality Adjusted HR: 1.30,
p ¼ 0.17
40%
D’Ancona et al., 2011 (14) 322 TAVR
(ES)
79  8 51  15 6.2 1 Mortality 16% vs. 19%,
p ¼ 0.30
NA
Buellesfeld et al., 2012 (15) 352 TAVR
(ES, CV)
83  6 51  15 32.1 1 Mortality
Death, stroke, and MI
Adjusted HR: 1.06,
p ¼ 0.90
Adjusted HR: 0.98,
p ¼ 0.98
NA
De Carlo et al., 2012 (13) 275 TAVR
(CV)
82  6 52  12 26.9 1.8 Mortality 12.5% vs. 11.8%,
p ¼ 0.90
NA
Urena et al., 2014 (12) 1,516 TAVR
(ES, CV)
80  8 55  14 15.4 1.9  1.4 Mortality
Death or rehospitalization
for HF
Adjusted HR: 0.98,
p ¼ 0.87
Adjusted HR: 1.0,
p ¼ 0.98
66.9% (on ECG)
Nazif et al., 2014 (2) 1,763 TAVR
(ES)
84  7 54 8.8 1 Mortality
Death and any
rehospitalization
26% vs. 18%,
p ¼ 0.08
42% vs. 33%,
p ¼ 0.007
50.5% (on ECG)
Values are n, mean  SD, or %, unless otherwise indicated.
CV ¼ CoreValve (Medtronic, Minneapolis, Minnesota); ECG ¼ electrocardiogram; ES ¼ Edwards Sapien (Edwards Lifesciences, Irvine, California); HF ¼ heart failure; HR ¼ hazard ratio; LVEF ¼ left
ventricular ejection fraction; MI ¼ myocardial infarction; NA ¼ not available; PPM ¼ permanent pacemaker; SAVR ¼ surgical aortic valve replacement; TAVR ¼ transcatheter aortic valve replacement.
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71PPM independently of prosthesis implantation depth
needs to be conﬁrmed. In fact, a higher (more aortic)
implantation of the transcatheter valve has been the
only maneuver associated with a reduction in the
need for PPM after TAVR (5), although perhaps at
the price of a potential increase in the risk of valve
embolization or malpositioning.
Solid evidence supports pacing-induced heart dis-
ease (6). The electrical and mechanical dyssynchrony
associated with right ventricular pacing leads to
an acute increase in left ventricular ﬁlling pres-
sures, a decrease in cardiac output, an increase in
sympathetic activation, abnormalities in myocardial
perfusion, and ultimately, a chronic adverse left ven-
tricular remodeling (6,7). These pathophysiological
effects of right ventricular pacing translate into an
increased risk of atrial ﬁbrillation, clinical heart fail-
ure, and even mortality, with patients with pre-
existing heart failure or left ventricular dysfunction
at highest risk (8–11). To date, however, studies as-
sessing the impact of PPM implantation after both
cardiac surgery and TAVR have failed to demonstrate
a negative effect of PPM on clinical outcomes (Table 1)
(2,12–17). There may be several reasons for this dis-
crepancy. First, the proﬁle of patients included in
studies assessing the impact of right ventricular
pacing differs from those included in surgical aortic
valve replacement and particularly TAVR studies,
who tend to be older and to more frequently experi-
ence severe noncardiac comorbidities. Second, it has
been shown that the clinical effect of right ventricularpacing becomes apparent ﬁrst in patients with left
ventricular dysfunction, and long periods of ventric-
ular pacing (usually >3 years) are required for the
occurrence of clinically-overt heart failure in patients
with normal left ventricular function (9,18,19), who
in fact currently represent approximately two-thirds
of patients undergoing TAVR. Indeed, the longest
reported follow-up for TAVR patients in studies
assessing the effect of PPM implantation is <2 years,
probably not long enough to see such clinical con-
sequences. Third, the percentage of cumulative pac-
ing has been shown to be a strong predictor of the
occurrence of heart failure (20–22), and more than
50% of patients requiring PPM after TAVR are not
pacing-dependent at 1-year follow up (23).
Unlike previous TAVR studies (12–15), Nazif et al.
(2) reported poorer clinical outcomes in patients
needing PPM implantation after TAVR, with an
increased rate of the combined endpoint of 1-year
all-cause mortality or repeat hospitalization for any
cause (42.0% vs. 32.6%, p ¼ 0.007) and a trend toward
a higher risk of 1-year all-cause mortality (26.3%
vs. 20.8%, p ¼ 0.08) in patients requiring PPM.
It is noteworthy that this excess mortality was
driven (surprisingly) by noncardiovascular deaths,
whereas no differences were observed in cardiovas-
cular deaths (7.6% vs. 9.0% in the PPM vs. no PPM
groups, respectively, p ¼ 0.52). Although this study
has the strengths of including a large number of
patients and using an event adjudication committee
to ensure data quality, the results were not adjusted
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72for potential confounders, such as the occurrence
of renal failure requiring dialysis and the need for
hemodynamic support during the TAVR procedure,
both of which were more frequent in those patients
requiring PPM. Both the lack of multivariable ad-
justment and the absence of explanation for the
increased risk in noncardiovascular mortality in such
patients should prompt us to seek further conﬁrma-
tion of these ﬁndings before deﬁnite conclusions can
be drawn.
Also, unlike previous studies in the TAVR ﬁeld
(12,24), Nazif et al. (2) did not ﬁnd any effect of PPM
following TAVR on ventricular function over time,
up to 1-year follow-up. Although no data on pacing
dependency were provided, the low proportion of
patients with pacing on ECG (about 50%) despite the
fact that most PPM were implanted due to advanced
AVB suggests a high rate of recovery of the atrio-
ventricular conduction in such patients. This ﬁnding
may partially explain the lack of effect of PPM on
left ventricular ejection fraction in this study, and
highlights the need for further studies to determine
the predictors of long-term pacing requirement
post-TAVR to prevent potential complications and
avoid the costs derived from unnecessary PPM im-
plantation. Meanwhile, these results suggest that
criteria for and timing of PPM implantation after
TAVR, particularly in the presence of complete AVB,should probably be revisited, at least in those
patients receiving balloon-expandable transcatheter
valve prostheses. The presence of a transient in-
ﬂammatory process at the level of the conduction
system in some cases cannot be ruled out, and a more
prolonged delay in PPM implantation, similar to that
recommended in the presence of conduction distur-
bances following surgical aortic valve replacement
(25) may be advisable.
The occurrence of conduction disturbances and
the need for PPM remains an important problem of
TAVR. Although requiring further conﬁrmation, the
work of Nazif et al. (2) provides new insight into the
potential consequences of PPM implantation after
TAVR. In addition to the issue of PPM and mortality/
rehospitalization following TAVR, questions about
the best timing for PPM, long-term pacing require-
ments, and the association between PPM and heart
failure remain to be answered. To explore the possi-
bility of expanding TAVR toward lower-risk and
younger patients, future studies in this ﬁeld are
mandatory.
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